Navigation Links
Misconception on Treatment Options among Prostate Cancer Patients

According to a new study, men with prostate cancer are more influenced by anecdote, misconception and emotional changes, which prevents them //from trusting on clinical trial evidences.

Research showed misconceptions on the disease management options and comparing the anecdotal experiences of others with prostate cancer to their own conditions, eventhough their severity and treatment options were entirely different from them are the reasons for waving decision among patients.

While there are several treatment options for men with localized prostate cancer, clinical trials have failed to demonstrate one optimal therapy. Each treatment option has benefits and its own unique and significant adverse side effects. Radical prostatectomy, for example, has only minimal survival benefits compared to even observation, but is associated with complications, such as impotence and urinary incontinence. With no clear-cut medical guidance, patients must assume a greater role in deciding on treatment in the face of disquieting statistics and risk-benefit information.

To characterize the factors that influence men's treatment decisions, Thomas Denberg, M.D., Ph.D. of the University of Colorado at Denver and Health Sciences Center and colleagues interviewed 20 men newly diagnosed with localized prostate cancer before and after treatment.

Three factors characterized the patients' decisions: fear and uncertainty; misconceptions about treatment efficacy and risks; and anecdotal information about other's experiences with prostate cancer. Even though most patients knew prostate cancer grows slowly, such 'abstract knowledge did little to dispel the vividly frightening, yet unlikely prospect of prostate cancer suddenly 'blossoming,' the researchers write.

After urologists reviewed the risks and benefits of the treatment options, patients had poor recall of the information they were provided, often confused side effects and treatments, and
'"/>




Page: 1 2

Related medicine news :

1. Autism: Symposium to Discuss Myths and Misconceptions
2. Misconceptions Put AIDS Patients In Tight-Spot
3. Misconceptions About Eating Eggs Busted
4. Misconceptions About Pet Owners Health Condition Revealed
5. Rajasthan Launches Programs to Overcome Misconceptions About Childbirth
6. Advances in Treatment of Cataracts
7. Recommendations for Treatment of Blood Pressue
8. Treatment for Menieres disease
9. Treatment for pre-menstrual syndrome is ineffective
10. Better Treatment for obesity
11. Gene Treatment for Heart Disease
Post Your Comments:
(Date:8/29/2008)... CE Mark Opens Market to More Than 30 European ...a Medical, Inc. announced today,that it has succes...or ISO,13485 and the Medical Device Directive (for...use of the coveted CE Mark -- or Conformite Europe...System. This expands Hoana,s,patient safety reach ...
(Date:8/29/2008)... Allsup explains financial impl...ng calculators available to people with disabiliti...ocus) August 29, 2008 -- Deciding how to move forw... a personal matter, but it,s important that indivi...inancial options, according to http://www.allsup....
(Date:8/28/2008)... Revenues increase 138% versus Q2 2007 - Nine n... 28 /PRNewswire-FirstCall/ - CRH Medical Corporati...or the three and six months,ended June 30, 2008 (a...ee,months ended June 30, 2008 increased 138% to $1...in 2007. Revenue for the six months ended June,30,...
(Date:8/28/2008)...is verbal, financial and physical, especially for ...ug. 28 (HealthDay News) -- A new study says that 1...from various forms of abuse. , The University ...erbal abuse (9 percent), being taken advantage of ... percent). The team also found that seniors with p...
Breaking Medicine News(10 mins):Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 2Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 3Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 4Health News:Social Security Disability Can Be Key to Financial Future 2Health News:Social Security Disability Can Be Key to Financial Future 3Health News:Social Security Disability Can Be Key to Financial Future 4Health News:Social Security Disability Can Be Key to Financial Future 5Health News:Social Security Disability Can Be Key to Financial Future 6Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:13% of Seniors Report Being Mistreated 2
...y published in the May issue of The American Journ...portant role in males as well. Low levels of the f...ure in men, the study found. Those who had low lev...d the greatest risk. The study was conducted by S...
...cancer in women has occurred because of two common...edy from a prevalent chemotherapy medication. Carb...nd lung cancers, is getting known for its success ...tish scientists have conducted a research on mice ...
... anxiety disorder that develops after exposure to ...rding to a study it was found that Vietnam combat ...) //when compared with their non-combat exposed, i... suggests that these deficits are not acquired by ...
...rst partial face transplant patient reports great ...done 5 months back//. Isabelle Dinoire (dee-NWAHR...are more healed and she's recovered total feeling ... two has said she was under the influence of drugs...
Other Medicine News:Health News:Hip Fracture Risk Increases In Men Having Low Estrogen Levels 2Health News:Brain Abnormalities Raise the Risk of PTSD 2
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: